Literature DB >> 14738564

The severity of liver fibrosis is associated with high leptin levels in chronic hepatitis C.

T Piche1, F Vandenbos, A Abakar-Mahamat, G Vanbiervliet, E M Barjoan, G Calle, J Giudicelli, B Ferrua, C Laffont, S Benzaken, A Tran.   

Abstract

Recent attention has focused on the liver profibrogenic role of leptin in animal models. The purpose of this study was to evaluate the role of leptin and TNF-alpha in the severity of liver fibrosis in patients with chronic hepatitis C (CHC). We used a radioimmunoassay to determine serum leptin concentrations in 77 consecutive patients with CHC and 22 healthy controls. Leptin was correlated with liver histological (METAVIR) and metabolic indices. Sixty five patients had none to moderate liver fibrosis (F0-F2) and twelve severe fibrosis (F3-F4). Steatosis was observed in all but 27 patients. Leptin was significantly increased in patients compared with controls and was significantly more elevated in females both in patients and controls. The age, age at infection, prothrombin index, body mass index (BMI), triglycerides, glycaemia, ferritin, leptin and TNF-alpha, were associated with severe fibrosis. Steatosis was significantly more pronounced in patients with severe than those without or moderate fibrosis (P = 0.04). Only leptin was significantly and independently associated with severe fibrosis (OR = 1.2, CI 95%: 1.1-1.4, P = 0.03). Leptin was significantly associated with BMI (r = 0.64, P < 0.001) and glycaemia (r = 0.43, P < 0.001). Significant correlations were found between steatosis and BMI (r = 0.30, P < 0.01) and glycaemia (r = 0.30, P < 0.01). In patients with CHC and higher BMI and glycaemia levels, the severity of liver fibrosis is associated with serum leptin. TNF-alpha is a putative candidate involved in the mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738564     DOI: 10.1046/j.1365-2893.2003.00483.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  21 in total

1.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 2.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

3.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

Review 4.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

5.  Hormonal and cytokine implications in the pathophysiology of osteoporosis occurring in chronic liver diseases.

Authors:  Corina Lucaci; Monica Acalovschi
Journal:  Maedica (Buchar)       Date:  2012-12

6.  Adipokines levels are associated with the severity of liver disease in patients with alcoholic cirrhosis.

Authors:  Maria Kalafateli; Christos Triantos; Emmanuel Tsochatzis; Marina Michalaki; Efstratios Koutroumpakis; Konstantinos Thomopoulos; Venetsanea Kyriazopoulou; Eleni Jelastopulu; Andrew Burroughs; Chryssoula Lambropoulou-Karatza; Vasiliki Nikolopoulou
Journal:  World J Gastroenterol       Date:  2015-03-14       Impact factor: 5.742

7.  Hepatitis C virus infection and nonalcoholic steatohepatitis.

Authors:  Anish Patel; Stephen A Harrison
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

Review 8.  Bioconjugation of oligonucleotides for treating liver fibrosis.

Authors:  Zhaoyang Ye; Houssam S Hajj Houssein; Ram I Mahato
Journal:  Oligonucleotides       Date:  2007

Review 9.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

10.  High serum leptin is an independent risk factor for non-response patients with low viremia to antiviral treatment in chronic hepatitis C.

Authors:  Yuichiro Eguchi; Toshihiko Mizuta; Tsutomu Yasutake; Akitaka Hisatomi; Ryuichi Iwakiri; Iwata Ozaki; Kazuma Fujimoto
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.